BIO-FD&C Co.,Ltd.
Financials
Valuation Metrics
BIO-FD&C Co.,Ltd.'s Market Cap is ₩758B. At end of 2025 it was ₩1374B. Ranked #1471 of 2,421 in KR market (top 61%), #852 of 1,640 on KOSDAQ (top 52%), #157 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 75.83B KRW | KR#1,471/2,421 Sec#157/231 |
| Revenue | 19.53B KRW | KR#2,140/2,421 Sec#157/231 |
| Net Income | 6.39B KRW | KR#1,121/2,421 Sec#71/231 |
| Total Assets | 74.51B KRW | KR#1,975/2,421 Sec#163/231 |
| Net Assets | 70.96B KRW | KR#1,678/2,421 Sec#141/231 |
| Employees | 76 | KR#1,833/2,421 Sec#157/231 |
| Value | ||
| P/E | 11.86x | KR#916/2,421 Sec#51/231 |
| P/B | 1.07x | KR#1,525/2,421 Sec#96/231 |
| PEG | 4.37x | KR#812/2,421 Sec#51/231 |
| P/S | 3.88x | KR#2,076/2,421 Sec#133/231 |
| EV/EBITDA | 10.53x | KR#648/2,421 Sec#30/231 |
| FCF Yield | 8.31% | KR#676/2,421 Sec#32/231 |
| Profitability | ||
| ROE | 9.01% | KR#699/2,421 Sec#50/231 |
| ROA | 8.58% | KR#382/2,421 Sec#27/231 |
| Op. Margin | 31.22% | KR#55/2,421 Sec#13/231 |
| Revenue Growth | 12.64% | KR#778/2,421 Sec#76/231 |
| Earnings Growth | 2.71% | KR#807/2,421 Sec#51/231 |
| Financial Health | ||
| Debt Ratio | 5.00% | KR#36/2,421 Sec#11/231 |
| Total Debt | 100.0M KRW | KR#2,034/2,421 Sec#188/231 |
| FCF | 6.30B KRW | KR#844/2,421 Sec#56/231 |
| Cash | 11.73B KRW | KR#1,600/2,421 Sec#135/231 |
| Current Ratio | 19.09x | KR#28/2,421 Sec#12/231 |
| Net Debt/EBITDA | -1.91x | KR#248/2,421 Sec#11/231 |
| Performance | ||
| 1Y Return | -52.35% | KR#2,093/2,421 Sec#193/231 |
| 1M Return | -2.46% | KR#1,519/2,421 Sec#120/231 |
| From 52W High | -55.17% | KR#1,662/2,421 Sec#125/231 |
| 1Y MDD | -63.09% | KR#1,648/2,421 Sec#135/231 |
| Trading | ||
| Volume | 3,534 shares | KR#2,195/2,421 Sec#207/231 |
| Trading Value | 30.9M KRW | KR#2,017/2,421 Sec#205/231 |
| Foreign Own. | 10.98% | KR#442/2,421 Sec#36/231 |
| Per Share | ||
| EPS | 735 KRW | KR#849/2,421 Sec#61/231 |
| BPS | 8,160 KRW | KR#1,114/2,421 Sec#79/231 |
Company Info
Established in 2005, the company conducts research, development, and production of active and pharmacological substances based on its plant cell platform technology. With 18 years of accumulated expertise, it boasts the world's largest plant cell library and has established a Plant Cell Banking system for cryopreserving over 120 species. Utilizing the world's first SMART-RC² new technology with high-frequency waveform application, the company's mass culture process supplies various clients, realizing steady sales growth. BIOFD&C is headquartered in Yeonsu-gu, Incheon.